Vytrus Biotech SA

As of December 31, 2024, Vytrus Biotech SA carries a market capitalization of 16.25M, placing it among publicly traded companies globally. Its enterprise value stands at 16.20M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2024, Vytrus Biotech SA has 7.52M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Vytrus Biotech SA maintains a current ratio of 3.03, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, Vytrus Biotech SA's stock has gained approximately 154.24% over the past 52 weeks. The 50-day moving average sits at 16.05, while the 200-day moving average is 15.55.

As of December 31, 2024, Vytrus Biotech SA holds 2.53M in cash and equivalents against 2.48M in total debt, resulting in a net debt position of -51,688.62. Total book value stands at 7.29M, with working capital of 2.54M providing operational flexibility.